MedTrace Logo

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma

NCT03046953 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-07-16

Study results available
· View outcomes & findings →

Summary

The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refractory to or has relapsed following initial treatment.

Conditions

  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory

Interventions

DRUG

Avelumab

anti-PDL1 antibody

Sponsors & Collaborators

  • Bloodwise

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Simon Wagner, MD · Univeristy of Leicester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-08
Primary Completion
2020-07-31
Completion
2021-07-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03046953 on ClinicalTrials.gov